Recruiting

Testing a faster-acting pain reliever added to standard fibromyalgia treatment

Plain-English translation of NCT07230171 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated June 2026 · How we translate trials

This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.

What is this trial?

Fibromyalgia causes widespread chronic pain that is hard to treat with current medications, which can take weeks to work and don't help everyone. This trial is testing whether esketamine—a medication that works quickly—can be added to standard fibromyalgia drugs to help reduce pain more effectively. The study will compare people who receive the new treatment alongside standard care to those who receive standard care alone.

Current fibromyalgia treatments are slow to work and don't relieve pain well enough for many patients. This medication may work faster and could fill that gap when standard treatments aren't doing enough.

Do you qualify?

You likely qualify if…

you are 18 years or older with good thinking and communication skills
you have been diagnosed with fibromyalgia using standard diagnostic criteria
you have tried non-medication treatments (like physical therapy) without enough pain relief, and have not yet taken the standard fibromyalgia medications being tested
you have moderate to severe pain—a score of 4 or higher on a standard pain scale

You likely don't qualify if…

you have been previously treated with pregabalin or venlafaxine (two of the standard fibromyalgia medications) for any condition
you have received intravenous ketamine or esketamine before for chronic pain
you have a serious mental health condition such as schizophrenia, bipolar disorder, or severe personality disorder
you have a history of substance abuse, alcoholism, or illicit drug use
you have untreated sleep apnea, uncontrolled diabetes, heart disease, narrow-angle glaucoma, or are allergic to any of the study medications

What participation looks like

If you join this study, you will receive either standard fibromyalgia medications alone, or the same standard medications plus esketamine infusions (injections into your vein). The study will measure your pain levels and track how well the treatment works and any side effects over the treatment period. You will have regular visits to receive infusions and complete assessments to see how you're doing.

AI-generated summary from trial data · Jun 3, 2026 · Not medical advice

Trial locations(1 site)

China

Beijing Tiantan Hospital, Beijing, Beijing 100070, Beijing